Keytruda Market

ID: MRFR/HC/17660-HCR
128 Pages
Vikita Thakur
Last Updated: May 29, 2026
Keytruda Market Research Report Information By Cancer Type (Melanoma, Lung cancer, Hodgkin lymphoma, Stomach cancer and Urothelial carcinoma), By Distribution Channel (Hospital Pharmacies and Specialty Pharmacies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Cancer Type (USD Billion) | |
      1. 4.1.1 Melanoma | |
      2. 4.1.2 Lung cancer | |
      3. 4.1.3 Hodgkin lymphoma | |
      4. 4.1.4 Stomach cancer | |
      5. 4.1.5 Urothelial carcinoma |
    2. 4.2 Healthcare, BY Distribution Channel (USD Billion) | |
      1. 4.2.1 Hospital Pharmacies | |
      2. 4.2.2 Specialty Pharmacies |
    3. 4.3 Healthcare, BY Region (USD Billion) | |
      1. 4.3.1 North America | | |
        1. 4.3.1.1 US | | |
        2. 4.3.1.2 Canada | |
      2. 4.3.2 Europe | | |
        1. 4.3.2.1 Germany | | |
        2. 4.3.2.2 UK | | |
        3. 4.3.2.3 France | | |
        4. 4.3.2.4 Russia | | |
        5. 4.3.2.5 Italy | | |
        6. 4.3.2.6 Spain | | |
        7. 4.3.2.7 Rest of Europe | |
      3. 4.3.3 APAC | | |
        1. 4.3.3.1 China | | |
        2. 4.3.3.2 India | | |
        3. 4.3.3.3 Japan | | |
        4. 4.3.3.4 South Korea | | |
        5. 4.3.3.5 Malaysia | | |
        6. 4.3.3.6 Thailand | | |
        7. 4.3.3.7 Indonesia | | |
        8. 4.3.3.8 Rest of APAC | |
      4. 4.3.4 South America | | |
        1. 4.3.4.1 Brazil | | |
        2. 4.3.4.2 Mexico | | |
        3. 4.3.4.3 Argentina | | |
        4. 4.3.4.4 Rest of South America | |
      5. 4.3.5 MEA | | |
        1. 4.3.5.1 GCC Countries | | |
        2. 4.3.5.2 South Africa | | |
        3. 4.3.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Merck & Co (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Bristol-Myers Squibb (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Roche (CH) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 AstraZeneca (GB) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Novartis (CH) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Pfizer (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Eli Lilly (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Amgen (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY CANCER TYPE |
    7. 6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    8. 6.5 CANADA MARKET ANALYSIS BY CANCER TYPE |
    9. 6.6 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    10. 6.7 EUROPE MARKET ANALYSIS |
    11. 6.8 GERMANY MARKET ANALYSIS BY CANCER TYPE |
    12. 6.9 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    13. 6.10 UK MARKET ANALYSIS BY CANCER TYPE |
    14. 6.11 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    15. 6.12 FRANCE MARKET ANALYSIS BY CANCER TYPE |
    16. 6.13 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    17. 6.14 RUSSIA MARKET ANALYSIS BY CANCER TYPE |
    18. 6.15 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    19. 6.16 ITALY MARKET ANALYSIS BY CANCER TYPE |
    20. 6.17 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    21. 6.18 SPAIN MARKET ANALYSIS BY CANCER TYPE |
    22. 6.19 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    23. 6.20 REST OF EUROPE MARKET ANALYSIS BY CANCER TYPE |
    24. 6.21 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    25. 6.22 APAC MARKET ANALYSIS |
    26. 6.23 CHINA MARKET ANALYSIS BY CANCER TYPE |
    27. 6.24 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    28. 6.25 INDIA MARKET ANALYSIS BY CANCER TYPE |
    29. 6.26 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    30. 6.27 JAPAN MARKET ANALYSIS BY CANCER TYPE |
    31. 6.28 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    32. 6.29 SOUTH KOREA MARKET ANALYSIS BY CANCER TYPE |
    33. 6.30 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    34. 6.31 MALAYSIA MARKET ANALYSIS BY CANCER TYPE |
    35. 6.32 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    36. 6.33 THAILAND MARKET ANALYSIS BY CANCER TYPE |
    37. 6.34 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    38. 6.35 INDONESIA MARKET ANALYSIS BY CANCER TYPE |
    39. 6.36 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    40. 6.37 REST OF APAC MARKET ANALYSIS BY CANCER TYPE |
    41. 6.38 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    42. 6.39 SOUTH AMERICA MARKET ANALYSIS |
    43. 6.40 BRAZIL MARKET ANALYSIS BY CANCER TYPE |
    44. 6.41 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    45. 6.42 MEXICO MARKET ANALYSIS BY CANCER TYPE |
    46. 6.43 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    47. 6.44 ARGENTINA MARKET ANALYSIS BY CANCER TYPE |
    48. 6.45 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    49. 6.46 REST OF SOUTH AMERICA MARKET ANALYSIS BY CANCER TYPE |
    50. 6.47 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    51. 6.48 MEA MARKET ANALYSIS |
    52. 6.49 GCC COUNTRIES MARKET ANALYSIS BY CANCER TYPE |
    53. 6.50 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    54. 6.51 SOUTH AFRICA MARKET ANALYSIS BY CANCER TYPE |
    55. 6.52 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    56. 6.53 REST OF MEA MARKET ANALYSIS BY CANCER TYPE |
    57. 6.54 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    58. 6.55 KEY BUYING CRITERIA OF HEALTHCARE |
    59. 6.56 RESEARCH PROCESS OF MRFR |
    60. 6.57 DRO ANALYSIS OF HEALTHCARE |
    61. 6.58 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    62. 6.59 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    63. 6.60 SUPPLY / VALUE CHAIN: HEALTHCARE |
    64. 6.61 HEALTHCARE, BY CANCER TYPE, 2024 (% SHARE) |
    65. 6.62 HEALTHCARE, BY CANCER TYPE, 2024 TO 2035 (USD Billion) |
    66. 6.63 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE) |
    67. 6.64 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion) |
    68. 6.65 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    69. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    70. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    71. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    72. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    73. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    74. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    75. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    76. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    77. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    78. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    79. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    80. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    81. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    82. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    83. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    84. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    85. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    86. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    87. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    88. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    89. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    90. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    91. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    92. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    93. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    94. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    95. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    96. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    97. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    98. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    99. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    100. 7.32 ACQUISITION/PARTNERSHIP | |

Keytruda Market Segmentation

Keytruda Market By Cancer Type (USD Billion, 2025-2035)

  • Melanoma
  • Lung cancer
  • Hodgkin lymphoma
  • Stomach cancer
  • Urothelial carcinoma

Keytruda Market By Distribution Channel (USD Billion, 2025-2035)

  • Hospital Pharmacies
  • Specialty Pharmacies